AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24055444 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus-eluting stent (EES)
Number of subjects: 600
Study 24055444 — intervention group
Group type: COMPARATOR
Intervention: TAXUS paclitaxel-eluting stent (PES)
Number of subjects: 600
Study 22085126 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of topical lignocaine gel
Number of subjects: 50
Study 22085126 — intervention group
Group type: COMPARATOR
Intervention: 3‐min delay after lubrication with topical lignocaine gel
Number of subjects: 50
Study 19757875 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmentally appropriate music listening intervention
Number of subjects: 24
Study 19757875 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 24
Study 17001224 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise training program at 60% of peak VO2 three times a week for 8 weeks
Number of subjects: 52
Study 17001224 — intervention group
Group type: COMPARATOR
Intervention: Control group (avoided physical training)
Number of subjects: 52
Study 15542277 — intervention group
Group type: EXPERIMENTAL
Intervention: MO.MA system (Invatec s.r.l.)
Number of subjects: 42
Study 15542277 — intervention group
Group type: COMPARATOR
Intervention: Filter device (E.P.I. FilterWire, Boston Scientific Corp.)
Number of subjects: 42
Study 11789280 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated laparoscopy with Chinese herbal medicine (combination group)
Number of subjects: 152
Study 11789280 — intervention group
Group type: COMPARATOR
Intervention: Chinese herbal medicine (TCM group)
Number of subjects: 152
Study 11789280 — intervention group
Group type: COMPARATOR
Intervention: Danazol (WM group)
Number of subjects: 152
Study 9279969 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10-20 mg day-1
Number of subjects: 43
Study 9279969 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50-100 mg day-1
Number of subjects: 43
Study 8342402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 104
Study 8342402 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 10 micrograms/kg
Number of subjects: 104
Study 8342402 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.1 mg/kg
Number of subjects: 104
Study 8342402 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 10 micrograms/kg and Metoclopramide 0.1 mg/kg
Number of subjects: 104
Study 31677630 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 32
Study 31677630 — intervention group
Group type: COMPARATOR
Intervention: Control group (no resistance training)
Number of subjects: 32
Study 29168575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed tracheal tubes
Number of subjects: 0
Study 29168575 — intervention group
Group type: COMPARATOR
Intervention: Uncuffed tracheal tubes
Number of subjects: 0
Study 26888338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam (CS) 2 g/8 h/day, IV
Number of subjects: 0
Study 26888338 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (PIP-TAZO) 4.5 g/6 h/day, IV
Number of subjects: 0
Study 24636461 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP nasal spray (20mcg/day)
Number of subjects: 40
Study 24636461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23062763 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine plus lithium/divalproex
Number of subjects: 1326
Study 23062763 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus lithium/divalproex
Number of subjects: 1326
Study 19963428 — intervention group
Group type: EXPERIMENTAL
Intervention: Castor oil emulsion eyedrops (Allergan)
Number of subjects: 15
Study 18354365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 18354365 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60
Study 18354365 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60
Study 15725916 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 15725916 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study 12185379 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 to 300 mg/day)
Number of subjects: 44
Study 12185379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10622312 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9117814 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorphous hydrogel
Number of subjects: 0
Study 9117814 — intervention group
Group type: COMPARATOR
Intervention: Dextranomer paste
Number of subjects: 0
Study 1860557 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion rate of 120 mU.m‐2.min‐1
Number of subjects: 9
Study 1860557 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion rate of 40 mU.m‐2.m‐1
Number of subjects: 9
Study 1860557 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose lowered to 2.8 mM
Number of subjects: 9
Study 1860557 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose lowered to 2 mM
Number of subjects: 9
Study 1860557 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher insulin infusion rate
Number of subjects: 9
Study 6336864 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm intravenous metronidazole preoperatively and five intravenous doses of 500 mg metronidazole postoperatively
Number of subjects: 72
Study 6336864 — intervention group
Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 72
Study 30882953 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPP (Pro-Kolin Advanced)
Number of subjects: 148
Study 30882953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 28118538 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 25 mg
Number of subjects: 289
Study 28118538 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 50 mg
Number of subjects: 289
Study 28118538 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 100 mg
Number of subjects: 289
Study 28118538 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg
Number of subjects: 289
Study 28118538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 26649448 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose VM202 (n=20)
Number of subjects: 52
Study 26649448 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose VM202 (n=21)
Number of subjects: 52
Study 26649448 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 52
Study 24443876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg + MET
Number of subjects: 180
Study 24443876 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MET
Number of subjects: 180
Study 24443876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing weight loss (regardless of treatment arm)
Number of subjects: 180
Study 21816315 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT)
Number of subjects: 265
Study 21816315 — intervention group
Group type: COMPARATOR
Intervention: Delayed BAT initiation (Control Group B)
Number of subjects: 265
Study 21816315 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 265
Study 19008868 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechin-rich beverage (582.8 mg of catechins per day)
Number of subjects: 43
Study 19008868 — intervention group
Group type: COMPARATOR
Intervention: Control group (96.3 mg of catechins per day)
Number of subjects: 43
Study 17898242 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision aid + written information
Number of subjects: 149
Study 17898242 — intervention group
Group type: COMPARATOR
Intervention: Written information alone
Number of subjects: 149
Study 15206989 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC 400 microg once daily
Number of subjects: 19
Study 15206989 — intervention group
Group type: COMPARATOR
Intervention: FP 250 microg twice daily
Number of subjects: 19
Study 11207639 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (long course: 42-day tapering course)
Number of subjects: 40
Study 11207639 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (pulse course: repeatable 3-day pulse course)
Number of subjects: 40
Study 11207639 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (both treatment regimens)
Number of subjects: 40
Study 9488624 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 10 microg/kg/d
Number of subjects: 90
Study 9488624 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 30 microg/kg/d
Number of subjects: 90
Study 9488624 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 20-40 microg/kg/d
Number of subjects: 90
Study 7848993 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopantomograms (OPG)
Number of subjects: 35
Study 7848993 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone scans
Number of subjects: 35
Study 7848993 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans
Number of subjects: 35
Study 7848993 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI scans
Number of subjects: 35
Study 7848993 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct inspection after periosteal stripping
Number of subjects: 35
Study 3182309 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan (L-PAM) and prednisone (pred) therapy for 12 weeks followed by total bone marrow irradiation (TBMI) at a dose of 1500 cGy
Number of subjects: 20
Study 3182309 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bone marrow irradiation (TBMI) at a dose of 1500 cGy
Number of subjects: 20
Study 31038755 — intervention group
Group type: EXPERIMENTAL
Intervention: FMT capsules
Number of subjects: 20
Study 27269279 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg/0.05 ml)
Number of subjects: 80
Study 27269279 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (0.2 mg/ml)
Number of subjects: 80
Study 27269279 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IOP between groups
Number of subjects: 80
Study 27269279 — intervention group
Group type: COMPARATOR
Intervention: Bleb morphological features based on MBGS
Number of subjects: 80
Study 27269279 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 80
Study 25737472 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal electromyography (LEMG) of the thyroarytenoid muscles by different techniques
Number of subjects: 40
Study 23354008 — intervention group
Group type: EXPERIMENTAL
Intervention: AGEs inhibitor (benfotiamine [50 mg]+pyridoxamine [50 mg]+methylcobalamin [500 µg])
Number of subjects: 30
Study 21750558 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine-attributed skin toxicity (Cape-ST) grade 1-3
Number of subjects: 185
Study 21750558 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine-attributed skin toxicity (Cape-ST) grade 0
Number of subjects: 185
Study 19831167 — intervention group
Group type: EXPERIMENTAL
Intervention: New toothpaste containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride as MFP
Number of subjects: 80
Study 19831167 — intervention group
Group type: COMPARATOR
Intervention: Benchmark commercial desensitizing toothpaste containing 2% potassium ion, dosed as 5.0% potassium nitrate, and 1450 ppm fluoride as NaF
Number of subjects: 80
Study 15295247 — intervention group
Group type: EXPERIMENTAL
Intervention: Steri Strip Skin Closures
Number of subjects: 100
Study 15295247 — intervention group
Group type: COMPARATOR
Intervention: Dermabond
Number of subjects: 100
Study 11683426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (600 mg/day)
Number of subjects: 89
Study 11683426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 9629989 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) - single oral dose (7 mg x kg(‐1))
Number of subjects: 7
Study 9629989 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CRE) - repeated oral doses (3 x 100 mg x kg(‐1) x day(‐1)) for 3 days
Number of subjects: 7
Study 9629989 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of caffeine and creatine (CAF + CRE)
Number of subjects: 7
Study 9629989 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 7
Study 7930327 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management model (assignment of a geriatrician and a social worker as the primary managing team)
Number of subjects: 141
Study 7930327 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 141
Study 7930327 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management model
Number of subjects: 141
Study 3048147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial continuous display oxygen electrode
Number of subjects: 9
Study 3048147 — intervention group
Group type: COMPARATOR
Intervention: Conventional intermittent blood gas samples
Number of subjects: 9
Study 30172659 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA + EPA (4 g daily)
Number of subjects: 0
Study 30172659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29659856 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT-experimental group with alerts and access to physical abuse-specific order set
Number of subjects: 130
Study 29659856 — intervention group
Group type: COMPARATOR
Intervention: RCT-control group with no alerts but manual access to order set
Number of subjects: 130
Study 29659856 — intervention group
Group type: COMPARATOR
Intervention: Preintervention group with no alerts or access to order set
Number of subjects: 130
Study 29659856 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the physical abuse order set during the RCT
Number of subjects: 130
Study 29659856 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of the order set
Number of subjects: 130
Study 26997232 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored, nurse-led educational intervention
Number of subjects: 0
Study 26997232 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24863156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical management plus rigorous lifestyle intervention (LS/IMM)
Number of subjects: 120
Study 24863156 — intervention group
Group type: EXPERIMENTAL
Intervention: LS/IMM with Roux-en-Y gastric bypass (RYGB)
Number of subjects: 120
Study 23174634 — intervention group
Group type: EXPERIMENTAL
Intervention: ACUITY-PCI risk score
Number of subjects: 2538
Study 23174634 — intervention group
Group type: COMPARATOR
Intervention: GRACE and TIMI risk scores
Number of subjects: 2538
Study 20679737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting Balloon Angioplasty (CBA)
Number of subjects: 224
Study 20679737 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain Balloon Angioplasty (PBA)
Number of subjects: 224
Study 18188803 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation approach
Number of subjects: 363
Study 18188803 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour-medical rehabilitation approach
Number of subjects: 363
Study 18188803 — intervention group
Group type: COMPARATOR
Intervention: Assigned approach (either traditional or behaviour-medical)
Number of subjects: 363
Study 15855574 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir 0.1 units/kg
Number of subjects: 12
Study 15855574 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir 0.2 units/kg
Number of subjects: 12
Study 15855574 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir 0.4 units/kg
Number of subjects: 12
Study 15855574 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir 0.8 units/kg
Number of subjects: 12
Study 15855574 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir 1.6 units/kg
Number of subjects: 12
Study 15855574 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir 0.29 units/kg
Number of subjects: 12
Study 11935130 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 total gastrectomy (TG)
Number of subjects: 187
Study 11935130 — intervention group
Group type: COMPARATOR
Intervention: D2 total gastrectomy plus splenectomy (TGS)
Number of subjects: 187
Study 10051050 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 50
Study 10051050 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune
Number of subjects: 50
Study 7627529 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct vision
Number of subjects: 3
Study 7627529 — intervention group
Group type: COMPARATOR
Intervention: 2-D imaging
Number of subjects: 3
Study 7627529 — intervention group
Group type: COMPARATOR
Intervention: 3-D imaging
Number of subjects: 3
Study 7627529 — intervention group
Group type: COMPARATOR
Intervention: Electronic imaging (2-D and 3-D)
Number of subjects: 3
Study 2186616 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (ferrous sulfate or ferrous gluconate)
Number of subjects: 100
Study 2186616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6990208 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day spironolactone therapy
Number of subjects: 17
Study 6990208 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day spironolactone therapy
Number of subjects: 17
Study 6990208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6990208 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 17
Study 6990208 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day therapy
Number of subjects: 17
Study 31469752 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block
Number of subjects: 47
Study 31469752 — intervention group
Group type: COMPARATOR
Intervention: Control (no fascia iliaca block)
Number of subjects: 47
Study 30612238 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative rehabilitation (basic offer: 2 consultations and 12-week contact possibility)
Number of subjects: 132
Study 30612238 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative rehabilitation (group program participation)
Number of subjects: 132
Study 30612238 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative rehabilitation (individual consultations)
Number of subjects: 132
Study 30612238 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative rehabilitation (overall satisfaction)
Number of subjects: 132
Study 30612238 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative rehabilitation (multidisciplinary model)
Number of subjects: 132
Study 30612238 — intervention group
Group type: COMPARATOR
Intervention: Standard oncology treatment
Number of subjects: 132
Study 28316103 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated BMD loss (n = 237)
Number of subjects: 2473
Study 28316103 — intervention group
Group type: COMPARATOR
Intervention: Maintenance of BMD (n = 453)
Number of subjects: 2473
Study 28316103 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident hip fracture (n = 2473)
Number of subjects: 2473
Study 26383249 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtracting the standing oxygen cost (4.8 ± 0.4 mL·kg(‐1)·min(‐1))
Number of subjects: 11
Study 26383249 — intervention group
Group type: EXPERIMENTAL
Intervention: Net ES (level 4.09 ± 0.31, uphill 4.22 ± 0.37, downhill 4.16 ± 0.44 km·h(‐1))
Number of subjects: 11
Study 26383249 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross EOTS (level 7.49 ± 0.32, downhill 7.78 ± 0.33 km·h(‐1))
Number of subjects: 11
Study 25407539 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 102
Study 25407539 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 102
Study 25407539 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 102
Study 25407539 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 102
Study 21953311 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise (200 min/wk, 123 minutes average)
Number of subjects: 160
Study 21953311 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised exercise (200 min/wk, 77 minutes average)
Number of subjects: 160
Study 19021596 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 2.5 mg bevacizumab
Number of subjects: 29
Study 19021596 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 5.0 mg bevacizumab
Number of subjects: 29
Study 19021596 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 1.25 mg bevacizumab
Number of subjects: 29
Study 17982319 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg (plus orphenadrin 30 mg)
Number of subjects: 40
Study 17982319 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 40
Study 17982319 — intervention group
Group type: EXPERIMENTAL
Intervention: paracetamol 1 g
Number of subjects: 40
Study 17982319 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib 40 mg
Number of subjects: 40
Study 15179792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dan Shao Tang (DST) and western medicine
Number of subjects: 90
Study 15179792 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 90
Study 11749745 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 236
Study 11749745 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 236
Study 11749745 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 236
Study 11749745 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding index
Number of subjects: 236
Study 9848296 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) pretreatment for 14 days
Number of subjects: 83
Study 9848296 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OC pretreatment)
Number of subjects: 83
Study 7926350 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 32
Study 7926350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Number of subjects: 32
Study 7926350 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 32